RxDoctor Payments Data

A Karim Kaki, MD

Internal Medicine · Clewiston, FLNPI 1962419531

Payments from drug & device makers

$520in general payments, 2019–2025

Across 27 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$214
  • GSK$135
  • Abiomed$83
  • Pfizer$47
  • Novo Nordisk$29
  • Lilly USA, LLC$13

What the payments were for

  • Food & beverage$520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca13$214
GSK7$135
Abiomed1$83
Pfizer3$47
Novo Nordisk2$29
Lilly USA, LLC1$13

How this compares

$520 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,084
Medicare patients
170
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$94,563
MounjaroTirzepatide40$55,592
Xigduo XrDapaglifloz Propaned/Metformin40$41,930
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,706
ShingrixVaricella-Zoster Ge/As01b/Pf144$29,881
ArexvyRsvpref3 Antigen/As01e/Pf96$28,299
EliquisApixaban37$26,622
FarxigaDapagliflozin Propanediol15$14,719
JanumetSitagliptin Phos/Metformin Hcl21$13,104
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$7,675
XareltoRivaroxaban13$7,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,136
SymbicortBudesonide/Formoterol Fumarate11$3,775
Glipizide-MetforminGlipizide/Metformin Hcl45$2,418
Rosuvastatin Calcium239$2,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$94,56370 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$135$88,886280 claims
Lilly USA, LLCMounjaro$13$55,59240 claims
PfizerEliquis, Abrysvo$47$34,29763 claims
AstraZenecaFarxiga, Symbicort$214$18,49526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clewiston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →